Literature DB >> 11723241

Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.

E Ficker1, W Jarolimek, A M Brown.   

Abstract

The major subunit of the cardiac delayed rectifier current I(Kr) is encoded by the human ether a-go-go related gene (HERG). HERG/I(Kr) channels are blocked selectively by class III antiarrhythmic methanesulfonanilide drugs such as dofetilide. The binding site for methanesulfonanilides is believed to be similar for nonantiarrhythmic drugs such as antihistamines, antibiotics, and antipsychotics. To gain further insight into the binding site, we examined the minimal structural changes necessary to transform low-affinity binding of dofetilide by the related bovine ether a-go-go channel bEAG to high-affinity binding of HERG. Previously, it was shown that high-affinity binding in HERG required intact C-type inactivation; the bovine ether a-go-go K(+) channel (bEAG), unlike HERG, is noninactivating. Therefore, we introduced C-type inactivation into noninactivating bEAG using site-directed mutagenesis. Two point mutations in the pore region, T432S and A443S, were sufficient to produce C-type inactivation. Low concentrations of dofetilide produced block of bEAG T432S/A443S; unlike HERG, block was almost irreversible. Substitution of an additional amino acid in transmembrane domain S6 made the block reversible. Dofetilide blocked the triply mutated bEAG T432S/A443S/A453S with an IC(50) value of 1.1 microM. The blocking potency was 30-fold greater than bEAG WT and about one third that of HERG WT. We conclude that high affinity methanesulfonanilide binding to HERG channels is strongly dependent on C-type inactivation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11723241     DOI: 10.1124/mol.60.6.1343

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  31 in total

1.  Inactivation and recovery in Kv1.4 K+ channels: lipophilic interactions at the intracellular mouth of the pore.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2003-11-07       Impact factor: 5.182

2.  Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.

Authors:  Jun Chen; Guiscard Seebohm; Michael C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

Review 3.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

4.  The evolutionarily conserved residue A653 plays a key role in HERG channel closing.

Authors:  Svetlana Z Stepanovic; Franck Potet; Christina I Petersen; Jarrod A Smith; Jens Meiler; Jeffrey R Balser; Sabina Kupershmidt
Journal:  J Physiol       Date:  2009-04-30       Impact factor: 5.182

5.  Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.

Authors:  M J McPate; R S Duncan; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

6.  hERG subunit composition determines differential drug sensitivity.

Authors:  N Abi-Gerges; H Holkham; E M C Jones; C E Pollard; J-P Valentin; G A Robertson
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Proline scan of the HERG channel S6 helix reveals the location of the intracellular pore gate.

Authors:  Samrat Thouta; Stanislav Sokolov; Yuki Abe; Sheldon J Clark; Yen M Cheng; Tom W Claydon
Journal:  Biophys J       Date:  2014-03-04       Impact factor: 4.033

8.  hERG gating microdomains defined by S6 mutagenesis and molecular modeling.

Authors:  Sarah L Wynia-Smith; Anne Lynn Gillian-Daniel; Kenneth A Satyshur; Gail A Robertson
Journal:  J Gen Physiol       Date:  2008-11       Impact factor: 4.086

9.  Molecular determinants of hERG channel block by terfenadine and cisapride.

Authors:  Kaichiro Kamiya; Ryoko Niwa; Mikio Morishima; Haruo Honjo; Michael C Sanguinetti
Journal:  J Pharmacol Sci       Date:  2008-11-06       Impact factor: 3.337

10.  The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.

Authors:  Q Tang; Z-Q Li; W Li; J Guo; H-Y Sun; X-H Zhang; C-P Lau; H-F Tse; S Zhang; G-R Li
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.